Loading

logo

Journal of Cellular Immunology

ISSN: 2689-2812

Review Article Open Access
Volume 2 | Issue 3 | DOI: https://doi.org/10.33696/immunology.2.030

CD146-Positive Tumors are Associated with Venous Thromboembolism

A. Joshkon1, J. Stalin1, W. Traboulsi1, L. Vivancos-Stalin1, M. Nollet1, R. Lacroix1, R.Bachelier1, F. Dignat-George1, A. Bertaud1, A.S. Leroyer1, H. Fayyad-Kazan2, N. Bardin1, M.Blot-Chabaud1,*
  • 1Aix-Marseille University, INSERM, INRAE, C2VN, UFR Pharmacie, 27 Bd J. Moulin, 13005 Marseille, France
  • 2Laboratory of Cancer Biology and Molecular Immunology, Lebanese University-Faculty of Science, Hadath, Lebanon
+ Affiliations - Affiliations

Corresponding Author

Marcel Blot-Chabaud, marcel.blot-chabaud@laposte.net

Received Date: April 02, 2020

Accepted Date: April 22, 2020

Citation:

Joshkon A, Stalin J, Traboulsi W, Vivancos-Stalin L, Nollet M, Lacroix R, et al. CD146-Positive Tumors are Associated with Venous Thromboembolism. J Cell Immunol. 2020; 2(3): 116-123.


Copyright: © 2020 Joshkon A, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

The role of CD146 and its soluble form have been intensely reviewed in the processes of cancer and inflammation. However, how CD146 is linked to coagulation and thrombotic events remains unclear. The aim of this paper is to shed light on this topic and clarify the contribution of CD146 as a procoagulant factor.

 

Recommended Articles

Full Text
Cite
Download PDF
Author Information X

About Scientific Archives

Scientific Archives is a global publisher initiated with the mission of ensuring equal opportunity for accessing science to research community all over the world. Spreading research findings with great relevance to all channels without any barrier is our goal. We want to overcome the challenges of Open Access with ensured quality and transparency.

Read More